Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 8, 2017, Pages 1154-1161.e1

  Peyrin Biroulet, Laurent ^a   Van Assche, Gert ^b   Armuzzi, Alessandro ^c   Garcia Alvarez, Laura ^d   Lara, Nuria ^d   Black, Christopher M ^e   Khalifa, Ahmed ^f   Cornillie, Freddy ^f   Kachroo, Sumesh ^e  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d IQVIA   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f MSD International   (Switzerland)

Author keywords

Disease Activity; Golimumab; PURSUIT; Self monitoring

Indexed keywords

ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; CONTINUOUS CLINICAL RESPONSE; DISEASE ACTIVITY; DISEASE COURSE; DOCTOR PATIENT RELATION; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE; SELF MONITORING; SELF REPORT; TREATMENT RESPONSE; ULCERATIVE COLITIS; DISEASE MANAGEMENT; PATIENT SATISFACTION; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; DISEASE MANAGEMENT; HUMANS; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 85009348133     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.10.001     Document Type: Article

References (46)

1. Badia, X., Mearin, F., Balboa, A., et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmcoeconomics 20 (2002), 749–758.
2. Bernklev, T., Jahnsen, J., Henriksen, M., et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 12 (2006), 402–412.
3. Van Assche, G., Peyrin-Biroulet, L., Sturm, A., et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months: multicenter European cohort study. Dig Liver Dis 48 (2016), 592–600.
4. Peyrin-Biroulet, L., Van Assche, G., Sturm, A., et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the Ulcerative Colitis CARES Study: a real world-based study. Dig Liver Dis 48 (2016), 601–607.
5. Torres, J., Billioud, V., Peyrin-Biroulet, L., et al. Ulcerative colitis as a sole mucosal disease: another misunderstanding?. Gut, 61, 2012, 633.
6. Torres, J., Billioud, V., Sachar, D.B., et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 18 (2012), 1356–1363.
7. Choi, P.M., Zelig, M.P., Similarity of colorectal cancer in CD and UC: implications for carcinogenesis and prevention. Gut 35 (1994), 950–954.
8. Magro, F., Rodrigues, A., Vieira, A.I., et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 18 (2012), 573–583.
9. Lindsay, J.O., Bergman, A., Patel, A.S., et al. Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. Aliment Pharmacol Ther 41 (2015), 1066–1078.
10. Cornillie, F., Hanauer, S.B., Diamond, R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 63 (2014), 1721–1727.
11. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
12. Sandborn, W.J., Ghosh, S., Panes, J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367 (2012), 616–624.
13. Vermeire, S., O'Byrne, S., Williams, M., et al. Differentiation between etrolizumab (rhumab beta7) and placebo in the eucalyptus phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis. Gastroenterology, 144, 2013, S36.
14. Reinisch, W., Sandborn, W.J., Panaccione, R., et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 19 (2013), 1700–1709.
15. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
16. Bálint, A., Farkas, K., Palatka, K., et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. Journal of Crohn's and Colitis 10 (2016), 26–30.
17. Armuzzi, A., Pugliese, D., Danese, S., et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 20 (2014), 1368–1374.
18. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
19. Colombel JF, Reinisch WG, Gibson P, et al. Clinical outcomes in continuous clinical responders with moderately to severely active ulcerative colitis: sub-analyses from the PURSUIT-SC Maintenance Study. United European Gastroenterology Week (UEGW) 2014. Abstract in Conference Proceedings. October 18–22, 2014, Vienna, Austria.
20. Bassi, A., Tolley, K., Wiseman, G., et al. PTU-066 A model to assess the cost of flare in ulcerative colitis (UC) to the NHS. Gut, 63, 2014, A67.
21. Higgins, P.D., Schwartz, M., Mapili, J., et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 100 (2005), 355–361.
22. Walmsley, R.S., Ayres, R.C.S., Pounder, R.E., et al. A simple clinical colitis activity index. Gut 43 (1998), 29–32.
23. Jowett, S.L., Seal, C.J., Phillips, E., et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 38 (2003), 164–171.
24. Lewis, J.D., Chuai, S., Nessel, L., et al. Use of noninvasive components of the Mayo Score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 14 (2008), 1660–1666.
25. Reinisch W, Colombel JF, Feagan BG, et al. Patient-reported outcomes can be used to monitor Continuous Clinical Response in patients with moderately to severely active ulcerative colitis treated with golimumab: results from the PURSUIT Maintenance Study. UEGW 2015. Abstract in Conference Proceedings. October 24–28, 2015, Vienna, Austria.
26. Jairath, V., Khanna, R., Zou, G.Y., et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 42 (2015), 1200–1210.
27. Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
28. Kappelman, M.D., Long, M.D., Martin, C., et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12 (2014), 1315–1323.e2.
29. Spiegel, B.M., Hays, R.D., Bolus, R., et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 109 (2014), 1804–1814.
30. Saibil, F., Lai, E., Hayward, A., et al. Self-management for people with inflammatory bowel disease. Can J Gastroenterol 22 (2008), 281–287.
31. Panés, J., O'Connor, M., Peyrin-Biroulet, L., et al. Improving quality of care in inflammatory bowel disease: what changes can be made today?. Journal of Crohn's and Colitis 8 (2014), 919–926.
32. Moreau J, Marthey L, Trang C, et al. Impact of an education program on IBD patient's skills: a randomized, controlled multicenter study (ECIPE). UEGW 2015. Abstract in Conference Proceedings. October 24–28, 2015, Vienna, Austria.
33. Carlsen K, Jakobsen C, Hansen LF, et al. Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study. European Crohn's and Colitis Organisation (ECCO) (2016). Abstract in Conference Proceedings. March 16–19, 2016, Amsterdam, The Netherlands.
34. Gibson, P.G., Powell, H., Coughlan, J., et al. Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev, 2002, CD001005.
35. Miche, E., Herrmann, G., Wirtz, U., et al. Effects of education, self-care instruction and physical exercise on patients with chronic heart failure. Z Kardiol 92 (2003), 985–993.
36. Frantz, A.K., Breaking down the barriers to heart failure patient self-care. Home Healthcare Nurse Journal 22 (2004), 109–115.
37. Turnock, A.C., Walters, E.H., Walters, J.A., et al. Action plans for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, CD005074.
38. Marín-Jiménez, I., Nos, P., Domènech, E., et al. Diagnostic performance of the Simple Clinical Colitis Activity Index self-administered online at home by patients with ulcerative colitis: CRONICA-UC Study. Am J Gastroenterol 111 (2016), 261–268.
39. Reinisch W, Colombel JF, Sandborn W, et al. Golimumab maintenance treatment and fecal calprotectin predict continuous clinical response in ulcerative colitis. European Crohn's and Colitis Organisation (ECCO), Clinical: Therapy & Observation 2015. Abstract in Conference Proceedings. February 18–21, 2015, Barcelona, Spain.
40. Elkjaer, M., Burisch, J., Voxen, H.V., et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 31 (2010), 323–330.
41. Elkjaer, M., Shuhaibar, M., Burisch, J., et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care' approach. Gut 59 (2010), 1652–1661.
42. Elkjaer, M., E-health: Web-guided therapy and disease self-management in ulcerative colitis—impact on disease outcome, quality of life and compliance. Dan Med J, 59, 2012, B4478.
43. Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 2 (1955), 1041–1048.
44. Seo, M., Okada, M., Yao, T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87 (1992), 971–976.
45. Powell-Tuck, J., Brown, R.L., Lennard-Jones, J.E., A comparison of oral prednisolone given as a single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13 (1978), 833–837.
46. Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 317 (1987), 1625–1629.